Semax Research: Neuroprotection Mechanisms in

Overview of Semax

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4–7) sequence. It was developed in Russia in the 1980s and has been studied primarily as a nootropic and neuroprotective compound. Unlike the full ACTH peptide, Semax does not exhibit significant adrenocorticotropic activity. Its primary investigated mechanism in cell models involves modulation of neurotrophin signalling, particularly the BDNF/TrkB pathway.

BDNF Upregulation

The most consistently reported in vitro effect of Semax is upregulation of brain-derived neurotrophic factor (BDNF) expression. In rat cortical neuron cultures and human neuroblastoma (SH-SY5Y) cell lines, Semax treatment at picomolar to nanomolar concentrations has been shown to increase BDNF mRNA levels (RT-PCR) and secreted BDNF protein (ELISA) compared to vehicle controls. BDNF promotes neuronal survival, synaptic plasticity, and dendritic branching through TrkB receptor activation and downstream MAPK, PI3K/Akt, and PLC-γ signalling cascades. Semax-induced BDNF upregulation provides a plausible mechanistic link to the neuroprotective effects observed in oxidative stress models.

NGF Pathway Interactions

Beyond BDNF, Semax has been reported to increase nerve growth factor (NGF) expression in glial cell cultures, with NGF mRNA elevation detectable within 4 hours of treatment. NGF supports survival and differentiation of cholinergic neurons and sensory neurons. In PC12 cells (a pheochromocytoma line widely used to model neuronal differentiation), Semax potentiated NGF-induced neurite outgrowth as measured by axon length and branching. These findings suggest Semax acts upstream of neurotrophin expression rather than directly at neurotrophin receptors.

Oxidative Stress Protection

In models of oxidative neuronal injury (H2O2, glutamate excitotoxicity), Semax pre-treatment has been associated with reduced LDH (lactate dehydrogenase) release, a marker of membrane integrity and cell death, and decreased ROS (reactive oxygen species) generation as measured by DCFH-DA fluorescence assays. The mechanisms proposed include indirect antioxidant effects mediated by BDNF-driven upregulation of antioxidant enzymes (superoxide dismutase, catalase) and direct inhibition of the mitochondrial permeability transition pore, though the latter mechanism requires further characterisation.

Melanocortin Receptor Interactions

As an ACTH(4–7) analogue, Semax has weak affinity for melanocortin receptors (MC3R, MC4R). At concentrations above those typically used in neurotrophin studies (>1 μM), Semax can engage these receptors in recombinant cell expression systems. The relevance of melanocortin receptor activity to the neurotrophin and neuroprotection effects observed at lower concentrations is not established. Most published mechanistic studies use concentrations in the picomolar to nanomolar range where receptor selectivity is less characterised.

Frequently Asked Questions

What concentration of Semax is used in neuroprotection studies?

Published cell culture studies typically report activity at picomolar to low nanomolar concentrations (10⁻¹² to 10⁻⁸ M). BDNF upregulation has been reported at concentrations as low as 1 pM in some cortical neuron models. Researchers should conduct independent dose-response characterisation for each cell model used.

What is the difference between Semax and Selank?

Semax is an ACTH-derived peptide studied for BDNF/NGF upregulation and neuroprotection. Selank is a tuftsin analogue studied for GABA-A receptor modulation and anxiolytic effects. They act via distinct receptor systems and are often studied together in cognitive/neuroprotection research protocols.

Does Stackpure offer Semax in multiple formats?

Yes. Stackpure offers Semax as a lyophilised peptide vial, pre-mixed in bacteriostatic water, and nasal spray. A Semax + Selank combination stack is also available.